StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Investment analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

CEL-SCI Trading Up 2.5 %

CEL-SCI stock opened at $0.26 on Tuesday. The stock has a market cap of $21.97 million, a P/E ratio of -0.54 and a beta of 0.95. The company’s fifty day simple moving average is $0.29 and its 200-day simple moving average is $0.51. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. CEL-SCI has a 12 month low of $0.18 and a 12 month high of $2.39.

Institutional Investors Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC grew its holdings in CEL-SCI Co. (NYSE:CVM) by 40.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned approximately 0.26% of CEL-SCI worth $76,000 at the end of the most recent reporting period. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.